Stock BNXT BIONXT SOLUTIONS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company BioNxt Solutions Inc.

Equities

BNXT

CA0909741062

Pharmaceuticals

Market Closed - Canadian Securities Exchange
Other stock markets
 03:28:12 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.36 CAD 0.00% Intraday chart for BioNxt Solutions Inc. -22.58% -25.77%
Apr. 22 BioNxt Solutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 18 BioNxt Solutions Provides Update on Commercialization of ODF Cladribine Product for Multiple Sclerosis MT

Business Summary

BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany. The Company is also focused on regulatory approval and commercialization of medical products for European markets. The Company, through its subsidiary, 3a-diagnostics GmbH, offers diagnostic products, which include COVID-19 PCR Diagnostic Kit and Peri-Implantitis Oral Biosensor.

Sales per Business

CAD in Million2022Weight2023Weight Delta
Consulting Service and Other
100.0 %
0 91.1 % 0 100.0 % +37.45%

Sales per region

CAD in Million2022Weight2023Weight Delta
South Korea
71.9 %
-- 0 71.9 % -
Austria
21.9 %
0 89.9 % 0 21.9 % -69.44%
Germany
5.2 %
0 7.1 % 0 5.2 % -7.70%
Switzerland
0.9 %
0 1.2 % 0 0.9 % +1.93%

Managers

Managers TitleAgeSince
Hugh Rogers CEO
 Chief Executive Officer 44 17-12-11
P. Meagher DFI
 Director of Finance/CFO 39 21-11-18
Wolfgang Probst BRD
 Director/Board Member 43 18-12-11
Leigh Hughes PRN
 Corporate Officer/Principal - -
Markus Neukom PRN
 Corporate Officer/Principal - -
Roland Spleiss PRN
 Corporate Officer/Principal - 22-01-09

Members of the board

Members of the board TitleAgeSince
P. Meagher DFI
 Director of Finance/CFO 39 21-11-18
Hugh Rogers CEO
 Chief Executive Officer 44 17-12-11
Raimar Löbenberg BRD
 Director/Board Member 58 18-12-09
Wolfgang Probst BRD
 Director/Board Member 43 18-12-11

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 109,519,065 102,429,065 ( 93.53 %) 0 93.53 %

Shareholders

NameEquities%Valuation
Raimar Löbenberg
4.720 %
5,000,000 4.720 % 2 M $
Wolfgang Probst
1.041 %
1,102,500 1.041 % 386 978 $
Hugh Rogers
0.6716 %
711,500 0.6716 % 249 737 $
P. Meagher
0.0245 %
26,000 0.0245 % 9 126 $
Per Thoresen
0.000000 %
0 0.000000 % - $

Company contact information

BioNxt Solutions, Inc.

1820 Fir Street Suite 270

V6J 3B1, Vancouver

+780 818 6422

http://bionxt.com
address BioNxt Solutions Inc.(BNXT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BIONXT SOLUTIONS INC. Stock BioNxt Solutions Inc.
-25.77% 28.71M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.17% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
ABBVIE INC. Stock AbbVie Inc.
+7.95% 296B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.45% 233B
NOVARTIS AG Stock Novartis AG
+6.04% 201B
ROCHE HOLDING AG Stock Roche Holding AG
-10.51% 193B
PFIZER, INC. Stock Pfizer, Inc.
-12.26% 143B
AMGEN INC. Stock Amgen Inc.
-6.47% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BNXT Stock
  4. Company BioNxt Solutions Inc.